Navigation Links
The Complexities, Cost of Midwest Biotech Drug Development

CHICAGO In trying to explain the complexities of the biotech industry to investors, academics and start-up biotech companies, most people now understand that it is a long, painstaking and expensive process. What they don't understand is why.

A brief primer in the drug discovery and development process shows us the following pathway:



Logical questions to the above inc......

Full article >>> ese type of diseases by granting orphan drug designation. This designation provides a company with both fast-track review as well as seven years market exclusivity from the time the drug is actually approved by the FDA (independent of the drugs patent status).

Another situation with the FDA exists for drugs for life-threatening disea......

Full article >>> nt to 80 percent of the cost and about 60 percent of the time to develop a drug is in the clinical phase of development (testing in humans), it is critical to ask this question up front before even starting clinical trials.

It has been said that it costs up to $800 to $900 million for Big Pharma to develop a successful drug. That is a higher amount than you are citing. Why?
......

Full article >>> y.

Happy Thanksgiving! See you next week!

......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 11/24/03


Related biology technology :

1. Midwest life science stocks kept sizzling in Q2
2. Midwest life science stocks sizzle in a tepid first quarter
3. A Midwest passage to India, Part II
4. Midwest offers non-stop flight to North Carolina research park
5. A Midwest life-science odyssey comes full circle
6. Midwest hotter for healthcare investments
7. A Midwest small-cap, life-science surprise package
8. 2006: A mixed blessing for Midwest life science companies
9. Midwest gaining stature in nanotech research
10. Midwest colleges strong contenders for NIH funds
11. Japan on the rebound: Implications for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... , ... February 10, 2016 , ... ... the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor ... expecting to fill more than 100 tables for its annual event, which will ...
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces ... the secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment ... PROMPT study, which seeks to advance understanding of the hereditary risks for certain ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an ... treatment of Alzheimer’s disease, announced today it has been selected to present at the ... Breakers in Palm Beach, Florida. The purpose of the Forum is to help ...
(Date:2/9/2016)... 9, 2016  Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies ... organs, recently reported the Company,s operating results for ... 2016. Lonza America , Inc. (the ... year in the process of consummating an agreement ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
Breaking Biology News(10 mins):